Literature DB >> 32094547

Many mutations in one clinical-trial basket.

Elaine Mardis.   

Abstract

Keywords:  Cancer; Medical research

Year:  2018        PMID： 32094547     DOI： 10.1038/d41586-018-01312-x

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

2.  Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Authors:  Stéphane Oudard; Stéphane Culine; Yann Vano; François Goldwasser; Christine Théodore; Thierry Nguyen; Eric Voog; Eugeniu Banu; Annick Vieillefond; Franck Priou; Gaël Deplanque; Gwenaëlle Gravis; Alain Ravaud; Jean Michel Vannetzel; Jean-Pascal Machiels; Xavier Muracciole; Marie-France Pichon; Jacques-Olivier Bay; Reza Elaidi; Corine Teghom; François Radvanyi; Philippe Beuzeboc
Journal:  Eur J Cancer       Date:  2014-11-15       Impact factor: 9.162

Review 3.  Targeting HER2 in other tumor types.

Authors:  S Scholl; P Beuzeboc; P Pouillart
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

4.  Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.

Authors:  Thomas Powles; Robert A Huddart; Tony Elliott; Shah-Jalal Sarker; Charlotte Ackerman; Robert Jones; Syed Hussain; Simon Crabb; Satinder Jagdev; John Chester; Serena Hilman; Mark Beresford; Graham Macdonald; Sundar Santhanam; John A Frew; Andrew Stockdale; Simon Hughes; Daniel Berney; Simon Chowdhury
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

5.  Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Authors:  Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis
Journal:  Cancer Discov       Date:  2012-12-07       Impact factor: 39.397

6.  Lung cancer: intragenic ERBB2 kinase mutations in tumours.

Authors:  Philip Stephens; Chris Hunter; Graham Bignell; Sarah Edkins; Helen Davies; Jon Teague; Claire Stevens; Sarah O'Meara; Raffaella Smith; Adrian Parker; Andy Barthorpe; Matthew Blow; Lisa Brackenbury; Adam Butler; Oliver Clarke; Jennifer Cole; Ed Dicks; Angus Dike; Anja Drozd; Ken Edwards; Simon Forbes; Rebecca Foster; Kristian Gray; Chris Greenman; Kelly Halliday; Katy Hills; Vivienne Kosmidou; Richard Lugg; Andy Menzies; Janet Perry; Robert Petty; Keiran Raine; Lewis Ratford; Rebecca Shepherd; Alexandra Small; Yvonne Stephens; Calli Tofts; Jennifer Varian; Sofie West; Sara Widaa; Andrew Yates; Francis Brasseur; Colin S Cooper; Adrienne M Flanagan; Margaret Knowles; Suet Y Leung; David N Louis; Leendert H J Looijenga; Bruce Malkowicz; Marco A Pierotti; Bin Teh; Georgia Chenevix-Trench; Barbara L Weber; Siu T Yuen; Grace Harris; Peter Goldstraw; Andrew G Nicholson; P Andrew Futreal; Richard Wooster; Michael R Stratton
Journal:  Nature       Date:  2004-09-30       Impact factor: 49.962

7.  Oncogenic ERBB3 mutations in human cancers.

Authors:  Bijay S Jaiswal; Noelyn M Kljavin; Eric W Stawiski; Emily Chan; Chaitali Parikh; Steffen Durinck; Subhra Chaudhuri; Kanan Pujara; Joseph Guillory; Kyle A Edgar; Vasantharajan Janakiraman; Rolf-Peter Scholz; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Wenlin Yuan; Brock A Peters; Zhengyan Kan; Jeremy Stinson; Michelle Mak; Zora Modrusan; Charles Eigenbrot; Ron Firestein; Howard M Stern; Krishnaraj Rajalingam; Gabriele Schaefer; Mark A Merchant; Mark X Sliwkowski; Frederic J de Sauvage; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

8.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

Authors:  K Semba; N Kamata; K Toyoshima; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Authors:  David M Hyman; Sarina A Piha-Paul; Helen Won; Jordi Rodon; Cristina Saura; Geoffrey I Shapiro; Dejan Juric; David I Quinn; Victor Moreno; Bernard Doger; Ingrid A Mayer; Valentina Boni; Emiliano Calvo; Sherene Loi; Albert C Lockhart; Joseph P Erinjeri; Maurizio Scaltriti; Gary A Ulaner; Juber Patel; Jiabin Tang; Hannah Beer; S Duygu Selcuklu; Aphrothiti J Hanrahan; Nancy Bouvier; Myra Melcer; Rajmohan Murali; Alison M Schram; Lillian M Smyth; Komal Jhaveri; Bob T Li; Alexander Drilon; James J Harding; Gopa Iyer; Barry S Taylor; Michael F Berger; Richard E Cutler; Feng Xu; Anna Butturini; Lisa D Eli; Grace Mann; Cynthia Farrell; Alshad S Lalani; Richard P Bryce; Carlos L Arteaga; Funda Meric-Bernstam; José Baselga; David B Solit
Journal:  Nature       Date:  2018-01-31       Impact factor: 49.962
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.